世界のウイルスベクター&プラスミドDNA製造市場2021-2028:ベクタータイプ別(AAV、レンチウイルス)、ワークフロー別、用途別、最終用途別、疾患別、地域別

◆英語タイトル:Viral Vectors And Plasmid DNA Manufacturing Market Size, Share & Trends Analysis Report By Vector Type (AAV, Lentivirus), By Workflow, By Application, By End Use, By Disease, By Region, And Segment Forecasts, 2021 - 2028
◆商品コード:GV21MY036
◆発行会社(リサーチ会社):Grand View Research
◆発行日:2021年5月18日
◆ページ数:300
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:
◆販売価格オプション(消費税別)
Single UserUSD5,950 ⇒換算¥654,500見積依頼/購入/質問フォーム
Multi User/Five UserUSD6,950 ⇒換算¥764,500見積依頼/購入/質問フォーム
Global/corporate LicenseUSD8,950 ⇒換算¥984,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGrand View Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Grand View Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

グランドビューリサーチ社は、世界のウイルスベクター&プラスミドDNA製造市場規模が2028年までに86億ドルに達すると予測しています。2021年から2028年までに年平均18.8%成長する見通しです。本市場調査資料では、ウイルスベクター&プラスミドDNA製造の世界市場について調査し、エグゼクティブサマリー、調査手法、市場変動・動向・範囲、ウイルスベクター製造コスト、ウイルスベクター産出高分析、経済的考慮事項&課題、戦略的提携、ベクタータイプ別(アデノウイルス、レトロウイルス、アデノ随伴ウイルス(AAV)、レンチウイルス、プラスミドDNA)分析、ワークフロー別(アップストリーム、ダウンストリーム)分析、用途別(アンチセンス法&RNAi療法、遺伝子治療、細胞治療、ワクチン、研究)分析、最終用途別(医薬品&バイオ医薬品企業、研究所)分析、地域別分析、競争分析など、以下の構成でまとめております。
・エグゼクティブサマリー
・調査手法
・市場変動・動向・範囲
・ウイルスベクター製造コスト
・ウイルスベクター産出高分析
・経済的考慮事項&課題
・戦略的提携
・世界のウイルスベクター&プラスミドDNA製造市場規模:ベクタータイプ別(アデノウイルス、レトロウイルス、アデノ随伴ウイルス(AAV)、レンチウイルス、プラスミドDNA)
・世界のウイルスベクター&プラスミドDNA製造市場規模:ワークフロー別(アップストリーム、ダウンストリーム)
・世界のウイルスベクター&プラスミドDNA製造市場規模:用途別(アンチセンス法&RNAi療法、遺伝子治療、細胞治療、ワクチン、研究)
・世界のウイルスベクター&プラスミドDNA製造市場規模:最終用途別(医薬品&バイオ医薬品企業、研究所)
・世界のウイルスベクター&プラスミドDNA製造市場規模:地域別
・競争分析
【レポートの概要】

Table of Contents

Chapter 1 Executive Summary
1.1. Market Summary
Chapter 2 Research Methodology
2.1 Information Procurement
2.2 Information or Data Analysis
2.3 Market Model
2.3.1 Market analysis, by vector type
2.3.1.1 By characteristics/advantage & disadvantage
2.3.1.2 By clinical trials
2.3.1.3 By manufacturing service penetration/availability
2.3.2 Market study, by end use
2.3.3 Regional analysis
Chapter 3 Market Variables, Trends, & Scope
3.1 Market Segmentation & Scope
3.2 Market Dynamics
3.2.1 Market drivers analysis
3.2.1.1 Robust pipeline for gene therapies and viral vector vaccines
3.2.1.2 Technological advancemnets in manufacturing vectors
3.2.1.3 HIghly competitive market and various strategies undertaken by market entities
3.2.2 Market restraint analysis
3.2.2.1 Regulatory, scientific, and ethical challenges associated with gene therapy and viral vectors
3.2.3 Market challenge analysis
3.2.3.1 Production capacity challenges
3.2.3.2 Manufacturing challenges pertaining to large scale production of vectors
3.2.4 Market opportunity Analysis
3.2.4.1 Facility expansion for cell and gene therapies
3.3 COVID-19 Impact Analysis
3.4 Viral Vector Production: Stepwise Challenges & Solutions
3.4.1 Host cell production & banking Needs
3.4.2 Viral vector production, Fill & Finish: challenges & solutions
3.4.3 Viral vector production, analytics: challenges & solutions
3.5 Penetration & Growth Prospect Mapping for Vector Type, 2020
3.6 Industry Analysis – Porter’s
3.7 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
3.8 Penetration & Growth Prospect Mapping for Prominent Industry Players, 2020
3.9 Manufacturer’s Landscape
3.10 Viral Vector Production Capacity Mapping Analysis
3.10.1 North America: capacity & service mapping
3.10.2 Europe: capacity & service mapping
3.10.2.1 Cobra Biologics (Sweden and the U.K.)
3.10.2.2 Biovian (Finland)
3.10.2.3 Oxford Biomedica (U.K.)
3.10.2.4 Lonza Pharma & Biotech (The Netherlands)
3.10.2.5 FinVector Oy (Finland)
3.10.2.6 Fujifilm Diosynth Biotechnologies (Denmark)
3.10.2.7 Fujifilm Diosynth Biotechnologies (U.K.)
3.10.2.8 Catalent Inc. (Belgium)
3.10.2.9 Novasep (Belgium)
3.10.2.10 Exothera (Belgium)
3.10.2.11 Delphi Genetics SA (Belgium)
3.10.2.12 Yposkesi (France)
3.10.2.13 VIVEbiotech (Spain)
3.10.2.14 MolMed SpA (Italy)
3.10.2.15 Anemocyte (Italy)
3.11 List of Companies with Portfolio Comprising Vector-based Therapeutic Candidates
3.12 List of Vector Manufacturers
Chapter 4 Viral Vector Production: Costs
4.1 Cost Models for Viral Vector Production
4.1.1 Campaign model
4.1.2 Day rate model
4.1.3 Hybrid model
4.2 Viral Vector Manufacturing Pricing Analysis
4.2.1 Parameters affecting price
4.2.2 AAV: Pricing analysis
4.2.3 Lentivirus: Pricing analysis
4.2.4 Adenovirus: Pricing analysis
4.2.5 Retrovirus: Pricing analysis
4.2.6 Plasmid: Pricing analysis
4.2.7 Gene Synthesis Cost
4.2.8 Genes/ Gene Fragment Cost Analysis
Chapter 5 Viral Vector Production & Yield Analysis
5.1 Production Yields: Biomarin, Spark Therapeutics & Solid Biosciences
5.2 Various Modes of Vector Production to increase & achieve Target Doses
5.2.1 Adenoviral vectors
5.2.2 Gamma- retroviral (MLV – murineleukemia virus) vectors
5.2.3 Lentiviral vectors
5.2.4 AAV vectors
5.2.5 rAAV vectors
5.2.5.1 rAAV Production: challenges & solutions
5.3 Total vector quantity produced per day and yield volume using different cell culture systems
5.4 Measures undertaken to optimize manufacturing of viral vectors for cell and gene therapy
5.5 Analysis of large- and small-scale production of viral vectors based on batch size
5.5.1 Small-scale/laboratory-scale cell culture systems
5.5.2 Large-scale cell culture systems
5.6 Common Practices for Small-Scale (10-50L) Adenovirus Vector Manufacturing
Chapter 6 Viral Vector Manufacturing: Process Economic Considerations & Challenges
6.1. Technological Advances in Manufacturing
6.1.1. Stable producer cell lines
6.1.2 Transient production
6.1.3 Lentiviral vector production process
6.1.3.1 Developments in LentiVector platform
6.2 CoGs Analysis of the Baseline Process
6.2.1 Raw material
6.2.2 Labor costs
6.2.3 Process costs
6.3 Regulatory Expectations
6.4 Approaches for Viral Vector Supply Gene Therapy
6.4.1 Gene therapy manufacturing facilities: trends & types
6.4.2 Gene therapy road map: key external trends
Chapter 7 Viral Vector Manufacturing Market: Strategic Alliances
7.1 Is The Time Right To Invest In Gene Therapy Sector?
7.2 Strategic Approaches for Market Scale-Up
7.2.1 Partnership models
7.2.2 Acquisition
7.2.3 Minority interest (ownership)
7.2.4 Joint venture
7.2.5 Alliance
7.2.6 Franchise
7.3 Collaborations in Viral Vector Manufacturing Market
7.3.1 Breakthrough growth: Lonza, Oxford Biomedica & others
Chapter 8 Vector Type Business Analysis
8.1 Market: Vector Type Movement Analysis
8.2 Adenovirus
8.2.1 Global adenovirus market, 2017 – 2028 (USD Million)
8.3 Retrovirus
8.3.1 Global retrovirus market, 2017 – 2028 (USD Million)
8.4 Adeno-associated Virus (AAV)
8.4.1 AAV manufacturing: Operating CROs & CMOs/CDMOs
8.4.2 Global AAV market, 2017 – 2028 (USD Million)
8.5 Lentivirus
8.5.1 Global lentivirus market, 2017 – 2028 (USD Million)
8.6 Plasmid DNA
8.6.1 Global plasmid DNA market, 2017 – 2028 (USD Million)
8.7 Others
8.7.1 Global other vectors market, 2017 – 2028 (USD Million)
Chapter 9 Workflow Business Analysis
9.1 Market: Workflow Movement Analysis
9.2 Upstream Processing
9.2.1 Market estimates and forecast, 2017 – 2028 (USD Million)
9.2.2 Vector amplification and expansion
9.2.2.1 Market estimates and forecast, 2017 – 2028 (USD Million)
9.2.3 Vector recovery/harvesting
9.2.3.1 Market estimates and forecast, 2017 – 2028 (USD Million)
9.3 Downstream Processing
9.3.1 Market estimates and forecast, for 2017 – 2028 (USD Million)
9.3.2 Purification
9.3.2.1 Market estimates and forecast, 2017 – 2028 (USD Million)
9.3.3 Fill finish
9.3.3.1 Market estimates and forecast, 2017 – 2028 (USD Million)
Chapter 10 Application Business Analysis
10.1 Market: Application Movement Analysis
10.2 Antisense & RNAi Therapy
10.2.1 Market for antisense, & RNAi therapy, 2017 – 2028 (USD Million)
10.3 Gene Therapy
10.3.1 Market for gene therapy, 2017 – 2028 (USD Million)
10.4 Cell Therapy
10.4.1 Market for cell therapy, 2017 – 2028 (USD Million)
10.5 Vaccinology
10.5.1 Market for vaccinology, 2017 – 2028 (USD Million)
10.6 Research Applications
10.6.1 Market for research applications, 2017 – 2028 (USD Million)
Chapter 11 End-use Business Analysis
11.1 Market: End-use Movement Analysis
11.2 Pharmaceutical and Biopharmaceutical Companies
11.2.1 Market for pharmaceutical and biopharmaceutical companies, 2017 – 2028 (USD Million)
11.3 Research Institutes
11.3.1 Market for research institutes, 2017 – 2028 (USD Million)
Chapter 12 Disease Business Analysis
12.1 Market: Disease Movement Analysis
12.2 Cancer
12.2.1 Market for cancer, 2017 – 2028 (USD Million)
12.3 Genetic Disorders
12.3.1 Market for genetic disorders, 2017 – 2028 (USD Million)
12.4 Infectious Diseases
12.4.1 Market for infectious diseases, 2017 – 2028 (USD Million)
12.5 Other Diseases
12.5.1 Market for other diseases, 2017 – 2028 (USD Million)

【レポートの目次】

Table of Contents

Chapter 1 Executive Summary
1.1. Market Summary
Chapter 2 Research Methodology
2.1 Information Procurement
2.2 Information or Data Analysis
2.3 Market Model
2.3.1 Market analysis, by vector type
2.3.1.1 By characteristics/advantage & disadvantage
2.3.1.2 By clinical trials
2.3.1.3 By manufacturing service penetration/availability
2.3.2 Market study, by end use
2.3.3 Regional analysis
Chapter 3 Market Variables, Trends, & Scope
3.1 Market Segmentation & Scope
3.2 Market Dynamics
3.2.1 Market drivers analysis
3.2.1.1 Robust pipeline for gene therapies and viral vector vaccines
3.2.1.2 Technological advancemnets in manufacturing vectors
3.2.1.3 HIghly competitive market and various strategies undertaken by market entities
3.2.2 Market restraint analysis
3.2.2.1 Regulatory, scientific, and ethical challenges associated with gene therapy and viral vectors
3.2.3 Market challenge analysis
3.2.3.1 Production capacity challenges
3.2.3.2 Manufacturing challenges pertaining to large scale production of vectors
3.2.4 Market opportunity Analysis
3.2.4.1 Facility expansion for cell and gene therapies
3.3 COVID-19 Impact Analysis
3.4 Viral Vector Production: Stepwise Challenges & Solutions
3.4.1 Host cell production & banking Needs
3.4.2 Viral vector production, Fill & Finish: challenges & solutions
3.4.3 Viral vector production, analytics: challenges & solutions
3.5 Penetration & Growth Prospect Mapping for Vector Type, 2020
3.6 Industry Analysis – Porter’s
3.7 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
3.8 Penetration & Growth Prospect Mapping for Prominent Industry Players, 2020
3.9 Manufacturer’s Landscape
3.10 Viral Vector Production Capacity Mapping Analysis
3.10.1 North America: capacity & service mapping
3.10.2 Europe: capacity & service mapping
3.10.2.1 Cobra Biologics (Sweden and the U.K.)
3.10.2.2 Biovian (Finland)
3.10.2.3 Oxford Biomedica (U.K.)
3.10.2.4 Lonza Pharma & Biotech (The Netherlands)
3.10.2.5 FinVector Oy (Finland)
3.10.2.6 Fujifilm Diosynth Biotechnologies (Denmark)
3.10.2.7 Fujifilm Diosynth Biotechnologies (U.K.)
3.10.2.8 Catalent Inc. (Belgium)
3.10.2.9 Novasep (Belgium)
3.10.2.10 Exothera (Belgium)
3.10.2.11 Delphi Genetics SA (Belgium)
3.10.2.12 Yposkesi (France)
3.10.2.13 VIVEbiotech (Spain)
3.10.2.14 MolMed SpA (Italy)
3.10.2.15 Anemocyte (Italy)
3.11 List of Companies with Portfolio Comprising Vector-based Therapeutic Candidates
3.12 List of Vector Manufacturers
Chapter 4 Viral Vector Production: Costs
4.1 Cost Models for Viral Vector Production
4.1.1 Campaign model
4.1.2 Day rate model
4.1.3 Hybrid model
4.2 Viral Vector Manufacturing Pricing Analysis
4.2.1 Parameters affecting price
4.2.2 AAV: Pricing analysis
4.2.3 Lentivirus: Pricing analysis
4.2.4 Adenovirus: Pricing analysis
4.2.5 Retrovirus: Pricing analysis
4.2.6 Plasmid: Pricing analysis
4.2.7 Gene Synthesis Cost
4.2.8 Genes/ Gene Fragment Cost Analysis
Chapter 5 Viral Vector Production & Yield Analysis
5.1 Production Yields: Biomarin, Spark Therapeutics & Solid Biosciences
5.2 Various Modes of Vector Production to increase & achieve Target Doses
5.2.1 Adenoviral vectors
5.2.2 Gamma- retroviral (MLV – murineleukemia virus) vectors
5.2.3 Lentiviral vectors
5.2.4 AAV vectors
5.2.5 rAAV vectors
5.2.5.1 rAAV Production: challenges & solutions
5.3 Total vector quantity produced per day and yield volume using different cell culture systems
5.4 Measures undertaken to optimize manufacturing of viral vectors for cell and gene therapy
5.5 Analysis of large- and small-scale production of viral vectors based on batch size
5.5.1 Small-scale/laboratory-scale cell culture systems
5.5.2 Large-scale cell culture systems
5.6 Common Practices for Small-Scale (10-50L) Adenovirus Vector Manufacturing
Chapter 6 Viral Vector Manufacturing: Process Economic Considerations & Challenges
6.1. Technological Advances in Manufacturing
6.1.1. Stable producer cell lines
6.1.2 Transient production
6.1.3 Lentiviral vector production process
6.1.3.1 Developments in LentiVector platform
6.2 CoGs Analysis of the Baseline Process
6.2.1 Raw material
6.2.2 Labor costs
6.2.3 Process costs
6.3 Regulatory Expectations
6.4 Approaches for Viral Vector Supply Gene Therapy
6.4.1 Gene therapy manufacturing facilities: trends & types
6.4.2 Gene therapy road map: key external trends
Chapter 7 Viral Vector Manufacturing Market: Strategic Alliances
7.1 Is The Time Right To Invest In Gene Therapy Sector?
7.2 Strategic Approaches for Market Scale-Up
7.2.1 Partnership models
7.2.2 Acquisition
7.2.3 Minority interest (ownership)
7.2.4 Joint venture
7.2.5 Alliance
7.2.6 Franchise
7.3 Collaborations in Viral Vector Manufacturing Market
7.3.1 Breakthrough growth: Lonza, Oxford Biomedica & others
Chapter 8 Vector Type Business Analysis
8.1 Market: Vector Type Movement Analysis
8.2 Adenovirus
8.2.1 Global adenovirus market, 2017 – 2028 (USD Million)
8.3 Retrovirus
8.3.1 Global retrovirus market, 2017 – 2028 (USD Million)
8.4 Adeno-associated Virus (AAV)
8.4.1 AAV manufacturing: Operating CROs & CMOs/CDMOs
8.4.2 Global AAV market, 2017 – 2028 (USD Million)
8.5 Lentivirus
8.5.1 Global lentivirus market, 2017 – 2028 (USD Million)
8.6 Plasmid DNA
8.6.1 Global plasmid DNA market, 2017 – 2028 (USD Million)
8.7 Others
8.7.1 Global other vectors market, 2017 – 2028 (USD Million)
Chapter 9 Workflow Business Analysis
9.1 Market: Workflow Movement Analysis
9.2 Upstream Processing
9.2.1 Market estimates and forecast, 2017 – 2028 (USD Million)
9.2.2 Vector amplification and expansion
9.2.2.1 Market estimates and forecast, 2017 – 2028 (USD Million)
9.2.3 Vector recovery/harvesting
9.2.3.1 Market estimates and forecast, 2017 – 2028 (USD Million)
9.3 Downstream Processing
9.3.1 Market estimates and forecast, for 2017 – 2028 (USD Million)
9.3.2 Purification
9.3.2.1 Market estimates and forecast, 2017 – 2028 (USD Million)
9.3.3 Fill finish
9.3.3.1 Market estimates and forecast, 2017 – 2028 (USD Million)
Chapter 10 Application Business Analysis
10.1 Market: Application Movement Analysis
10.2 Antisense & RNAi Therapy
10.2.1 Market for antisense, & RNAi therapy, 2017 – 2028 (USD Million)
10.3 Gene Therapy
10.3.1 Market for gene therapy, 2017 – 2028 (USD Million)
10.4 Cell Therapy
10.4.1 Market for cell therapy, 2017 – 2028 (USD Million)
10.5 Vaccinology
10.5.1 Market for vaccinology, 2017 – 2028 (USD Million)
10.6 Research Applications
10.6.1 Market for research applications, 2017 – 2028 (USD Million)
Chapter 11 End-use Business Analysis
11.1 Market: End-use Movement Analysis
11.2 Pharmaceutical and Biopharmaceutical Companies
11.2.1 Market for pharmaceutical and biopharmaceutical companies, 2017 – 2028 (USD Million)
11.3 Research Institutes
11.3.1 Market for research institutes, 2017 – 2028 (USD Million)
Chapter 12 Disease Business Analysis
12.1 Market: Disease Movement Analysis
12.2 Cancer
12.2.1 Market for cancer, 2017 – 2028 (USD Million)
12.3 Genetic Disorders
12.3.1 Market for genetic disorders, 2017 – 2028 (USD Million)
12.4 Infectious Diseases
12.4.1 Market for infectious diseases, 2017 – 2028 (USD Million)
12.5 Other Diseases
12.5.1 Market for other diseases, 2017 – 2028 (USD Million)

List of Tables

Table 1 Viral vector-based COVID-19 vaccine candidates
Table 2 Operating CMOs/CDMOs for advanced therapy manufacturing in EU
Table 3 Contract Manufacturing Organizations (CMOs) offering viral & non-viral vector manufacturing services
Table 4 Biozilla, LLC’s plasmid purification cost
Table 5 AAV production: Pricing analysis
Table 6 AAV packaging, cloning, & titration: Pricing analysis
Table 7 Lentivirus production: Pricing analysis
Table 8 Lentivirus packaging, titration, & others: Pricing analysis
Table 9 Adenovirus production: Pricing analysis
Table 10 Adenovirus packaging, titration, & others: Pricing analysis
Table 11 Retrovirus production: Pricing analysis
Table 12 Plasmid production: Pricing analysis
Table 13 Plasmid DNA purification: Pricing analysis
Table 14 Eurofins Genomics LLC’s gene synthesis cost analysis
Table 15 GenScript’s gene synthesis cost analysis (GenPlus Economy Gene Synthesis)
Table 16 Eurofins Genomics LLC’s gene fragments cost analysis
Table 17 Production yields of rAAV vectors using different production systems
Table 18 Large-scale production of MLV vectors for clinical applications
Table 19 Most-used 2D devices used for LV production
Table 20 Fixed-bed bioreactors optimized for high-scale LV production
Table 21 Overview of costs involved in cell therapy development
Table 22 Common raw/starting materials for viral vector manufacturing
Table 23 Sensitivity of baseline process to failure rates during cell therapy production
Table 24 AAV services of Vigene
Table 25 List of CROs & CMOs/CDMOs operating in the AAV market in the U.S.
Table 26 Human clinical trials in progress with viral vectored vaccines
Table 27 Clinical trials in cancer gene therapy
Table 28 List of key technology supplier for downstream processing
Table 29 List of key technology supplier for upstream processing
Table 30 Distributors list for Sartorius for key countries
Table 31 Distributors list for Cytiva for key countries
Table 32 List of key emerging companies
Table 33 North America viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2017 - 2028 (USD Million)
Table 34 North America viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2017 - 2028 (USD Million)
Table 35 North America upstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow, 2017 - 2028 (USD Million)
Table 36 North America downstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow, 2017 - 2028 (USD Million)
Table 37 North America viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 38 North America viral vector & plasmid DNA manufacturing market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
Table 39 North America viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2017 - 2028 (USD Million)
Table 40 U.S. viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2017 - 2028 (USD Million)
Table 41 U.S.viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2017 - 2028 (USD Million)
Table 42 U.S. upstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow 2017 - 2028 (USD Million)
Table 43 U.S. downstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow, 2017 - 2028 (USD Million)
Table 44 U.S. viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 45 U.S.viral vector & plasmid DNA manufacturing market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
Table 46 U.S.viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2017 - 2028 (USD Million)
Table 47 Canada viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2017 - 2028 (USD Million)
Table 48 Canada viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2017 - 2028 (USD Million)
Table 49 Canada upstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow 2017 - 2028 (USD Million)
Table 50 Canada downstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow, 2017 - 2028 (USD Million)
Table 51 Canada viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 52 Canada viral vector & plasmid DNA manufacturing market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
Table 53 Canada viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2017 - 2028 (USD Million)
Table 54 Europe viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2017 - 2028 (USD Million)
Table 55 Europe viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2017 - 2028 (USD Million)
Table 56 Europe upstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow, 2017 - 2028 (USD Million)
Table 57 Europe downstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow, 2017 - 2028 (USD Million)
Table 58 Europe viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 59 Europe viral vector & plasmid DNA manufacturing market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
Table 60 Europe viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2017 - 2028 (USD Million)
Table 61 U.K. viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2017 - 2028 (USD Million)
Table 62 U.K. viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2017 - 2028 (USD Million)
Table 63 U.K. upstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow, 2017 - 2028 (USD Million)
Table 64 U.K. downstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow, 2017 - 2028 (USD Million)
Table 65 U.K. viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 66 U.K. viral vector & plasmid DNA manufacturing market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
Table 67 U.K. viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2017 - 2028 (USD Million)
Table 68 Germany viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2017 - 2028 (USD Million)
Table 69 Germany viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2017 - 2028 (USD Million)
Table 70 Germany upstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow, 2017 - 2028 (USD Million)
Table 71 Germany downstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow, 2017 - 2028 (USD Million)
Table 72 Germany viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 73 Germany viral vector & plasmid DNA manufacturing market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
Table 74 Germany viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2017 - 2028 (USD Million)
Table 75 France viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2017 - 2028 (USD Million)
Table 76 France viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2017 - 2028 (USD Million)
Table 77 France upstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow, 2017 - 2028 (USD Million)
Table 78 France downstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow, 2017 - 2028 (USD Million)
Table 79 France viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 80 France viral vector & plasmid DNA manufacturing market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
Table 81 France viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2017 - 2028 (USD Million)
Table 82 Italy viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2017 - 2028 (USD Million)
Table 83 Italy viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2017 - 2028 (USD Million)
Table 84 Italy upstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow, 2017 - 2028 (USD Million)
Table 85 Italy downstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow, 2017 - 2028 (USD Million)
Table 86 Italy viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 87 Italy viral vector & plasmid DNA manufacturing market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
Table 88 Italy viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2017 - 2028 (USD Million)
Table 89 Spain viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2017 - 2028 (USD Million)
Table 90 Spain viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2017 - 2028 (USD Million)
Table 91 Spain upstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow, 2017 - 2028 (USD Million)
Table 92 Spain downstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow, 2017 - 2028 (USD Million)
Table 93 Spain viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 94 Spain viral vector & plasmid DNA manufacturing market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
Table 95 Spain viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2017 - 2028 (USD Million)
Table 96 Asia Pacific viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2017 - 2028 (USD Million)
Table 97 Asia Pacific viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2017 - 2028 (USD Million)
Table 98 Asia Pacific upstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow, 2017 - 2028 (USD Million)
Table 99 Asia Pacific downstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow, 2017 - 2028 (USD Million)
Table 100 Asia Pacific viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 101 Asia Pacific viral vector & plasmid DNA manufacturing market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
Table 102 Asia Pacific viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2017 - 2028 (USD Million)
Table 103 China viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2017 - 2028 (USD Million)
Table 104 China viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2017 - 2028 (USD Million)
Table 105 China upstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow, 2017 - 2028 (USD Million)
Table 106 China downstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow, 2017 - 2028 (USD Million)
Table 107 China viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 108 China viral vector & plasmid DNA manufacturing market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
Table 109 China viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2017 - 2028 (USD Million)
Table 110 Japan viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2017 - 2028 (USD Million)
Table 111 Japan viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2017 - 2028 (USD Million)
Table 112 Japan upstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow, 2017 - 2028 (USD Million)
Table 113 Japan downstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow, 2017 - 2028 (USD Million)
Table 114 Japan viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 115 Japan viral vector & plasmid DNA manufacturing market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
Table 116 Japan viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2017 - 2028 (USD Million)
Table 117 India viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2017 - 2028 (USD Million)
Table 118 India viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2017 - 2028 (USD Million)
Table 119 India upstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow, 2017 - 2028 (USD Million)
Table 120 India downstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow, 2017 - 2028 (USD Million)
Table 121 India viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 122 India viral vector & plasmid DNA manufacturing market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
Table 123 India viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2017 - 2028 (USD Million)
Table 124 South Korea viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2017 - 2028 (USD Million)
Table 125 South Korea viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2017 - 2028 (USD Million)
Table 126 South Korea upstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow, 2017 - 2028 (USD Million)
Table 127 South Korea downstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow, 2017 - 2028 (USD Million)
Table 128 South Korea viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 129 South Korea viral vector & plasmid DNA manufacturing market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
Table 130 South Korea viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2017 - 2028 (USD Million)
Table 131 Latin America viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2017 - 2028 (USD Million)
Table 132 Latin America viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2017 - 2028 (USD Million)
Table 133 Latin America upstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow, 2017 - 2028 (USD Million)
Table 134 Latin America downstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow, 2017 - 2028 (USD Million)
Table 135 Latin America viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 136 Latin America viral vector & plasmid DNA manufacturing market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
Table 137 Latin America viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2017 - 2028 (USD Million)
Table 138 Brazil viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2017 - 2028 (USD Million)
Table 139 Brazil viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2017 - 2028 (USD Million)
Table 140 Brazil upstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow, 2017 - 2028 (USD Million)
Table 141 Brazil downstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow, 2017 - 2028 (USD Million)
Table 142 Brazil viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 143 Brazil viral vector & plasmid DNA manufacturing market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
Table 144 Brazil viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2017 - 2028 (USD Million)
Table 145 Mexico viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2017 - 2028 (USD Million)
Table 146 Mexico viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2017 - 2028 (USD Million)
Table 147 Mexico upstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow, 2017 - 2028 (USD Million)
Table 148 Mexico downstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow, 2017 - 2028 (USD Million)
Table 149 Mexico viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 150 Mexico viral vector & plasmid DNA manufacturing market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
Table 151 Mexico viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2017 - 2028 (USD Million)
Table 152 MEA viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2017 - 2028 (USD Million)
Table 153 MEA viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2017 - 2028 (USD Million)
Table 154 MEA upstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow, 2017 - 2028 (USD Million)
Table 155 MEA downstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow, 2017 - 2028 (USD Million)
Table 156 MEA viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 157 MEA viral vector & plasmid DNA manufacturing market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
Table 158 MEA viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2017 - 2028 (USD Million)
Table 159 South Africa viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2017 - 2028 (USD Million)
Table 160 South Africa viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2017 - 2028 (USD Million)
Table 161 South Africa upstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow, 2017 - 2028 (USD Million)
Table 162 South Africa downstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow, 2017 - 2028 (USD Million)
Table 163 South Africa viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 164 South Africa viral vector & plasmid DNA manufacturing market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
Table 165 South Africa viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2017 - 2028 (USD Million)
Table 166 Saudi Arabia viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2017 - 2028 (USD Million)
Table 167 Saudi Arabia viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2017 - 2028 (USD Million)
Table 168 Saudi Arabia upstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow 2017 - 2028 (USD Million)
Table 169 Saudi Arabia downstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow, 2017 - 2028 (USD Million)
Table 170 Saudi Arabia viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 171 Saudi Arabia viral vector & plasmid DNA manufacturing market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
Table 172 Saudi Arabia viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2017 - 2028 (USD Million)




List of Figures

Fig. 1 Market snapshot, 2020 (USD Million)
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Primary research process
Fig. 5 Primary research validation
Fig. 6 Market research approaches
Fig. 7 Value-chain-based sizing & forecasting
Fig. 8 QFD modeling
Fig. 9 Market formulation & validation
Fig. 10 Vector type characteristic analysis
Fig. 11 QFD model assessment for vector type
Fig. 12 Vector type characteristic analysis
Fig. 13 Lentiviral vectors versus AAV vectors
Fig. 14 Global number of AAV- and lentivirus-based clinical trials
Fig. 15 Gene therapy approvals versus clinical trials
Fig. 16 Some major industry sponsors of CAR T cell clinical trials, as of September 2019
Fig. 17 Distribution of the sponsors of advanced therapies clinical trials, 2016
Fig. 18 Distribution of noncommercial sponsors of ATMP clinical trials, 2016
Fig. 19 Gene therapy approvals versus clinical trials
Fig. 20 Penetration by end use settings
Fig. 21 Regional analysis for rare disease genetic testing market
Fig. 22 U.K. cell and gene therapy manufacturing capacity, 2016 to 2019
Fig. 23 Number of gene therapy sites across gene therapy and multifunctional facilities in the U.K., 2019
Fig. 24 Market trends & outlook
Fig. 25 Market segmentation & scope
Fig. 26 Market driver relevance analysis (Current & future impact)
Fig. 27 Gene therapy clinical trials
Fig. 28 Viral vectors used in clinical trials
Fig. 29 Key strategies by market players to drive success in gene therapy arena
Fig. 30 Recent and upcoming approved gene transfer-mediated programs
Fig. 31 Market restraint relevance analysis (Current & future impact)
Fig. 32 Various ethical questions raised by gene therapy
Fig. 33 Major challenges in large-scale vector manufacturing
Fig. 34 Plasmid production: Challenges & solutions
Fig. 35 Host cell production & banking needs
Fig. 36 Viral vector production, F&F: challenges & solutions
Fig. 37 Viral vector production, analytics: Challenges & solutions
Fig. 38 Penetration & growth prospect mapping for vector type, 2020
Fig. 39 Porter’s Five Forces Analysis
Fig. 40 SWOT analysis, by factor (Political & Legal, Economic and Technological)
Fig. 41 Penetration & growth prospect mapping for prominent industry players, 2020
Fig. 42 Viral Vector Manufacturing Landscape
Fig. 43 List of companies with portfolio comprising vector-based therapeutic candidates
Fig. 44 List of vector manufacturers
Fig. 45 Comparison of costs estimated by campaign, day rate, and hybrid models
Fig. 46 Campaign model for viral vector production
Fig. 47 Day rate model for viral vector production
Fig. 48 Hybrid model for viral vector production
Fig. 49 VIRAL VECTOR PRODUCTION UNIT’s AAV production cost by application
Fig. 50 Kerafast, Inc.’s lentivirus production cost by titer
Fig. 51 Comparative analysis: Biozilla's service vs. commercial kit
Fig. 52 Company-wise: Vector yields
Fig. 53 Prevailing Technologies for AAV Production
Fig. 54 rAAV Production: Challenges & Solutions
Fig. 55 iCELLis systems: Productivities
Fig. 56 Small- & large-scale cell culture systems for production of viral vectors
Fig. 57 Process flow diagram for common practices for small-scale (10–50 L) adenoviral vector purification
Fig. 58 Breakdown of CoGs per process for cell therapy manufacture
Fig. 59 Progression of cGMP compliance at different product development stages
Fig. 60 Standardization & Regulatory Challenges
Fig. 61 Gene Therapy Manufacturing Facilities: Trends & Types
Fig. 62 Gene Therapy Road Map: Key External Trends
Fig. 63 Strategic Approaches for Market Scale-Up
Fig. 64 Viral vector & plasmid DNA manufacturing market: Vector type outlook key takeaways
Fig. 65 Viral vector & plasmid DNA manufacturing market: Vector type movement analysis
Fig. 66 Global adenovirus market, 2017 - 2028 (USD Million)
Fig. 67 Global Retrovirus market, 2017 - 2028 (USD Million)
Fig. 68 Global AAV market, 2017 - 2028 (USD Million)
Fig. 69 Global Lentivirus market, 2017 - 2028 (USD Million)
Fig. 70 Global Plasmid DNA market, 2017 - 2028 (USD Million)
Fig. 71 Global Other vectors market, 2017 - 2028 (USD Million)
Fig. 72 Viral vector & plasmid DNA manufacturing market : Workflow outlook and key takeaways
Fig. 73 Global viral vector & plasmid DNA manufacturing market: Workflow movement analysis
Fig. 74 Global upstream processing market estimates and forecast 2017 - 2028 (USD Million)
Fig. 75 Global vector amplification and expansion market estimates and forecast 2017 - 2028 (USD Million)
Fig. 76 Global vector recovery/harvesting market estimates and forecast 2017 - 2028 (USD Million)
Fig. 77 Global downstream processing market estimates and forecast, for 2017 - 2028 (USD Million)
Fig. 78 Global purification market estimates and forecast 2017 - 2028 (USD Million)
Fig. 79 Global fill finish market estimates and forecast 2017 - 2028 (USD Million)
Fig. 80 Viral vector & plasmid DNA manufacturing market : Application outlook and key takeaways
Fig. 81 Viral vector & plasmid DNA manufacturing market: Application movement analysis
Fig. 82 Global viral vector & plasmid DNA manufacturing market for antisense & RNAi therapy, 2017 - 2028 (USD Million)
Fig. 83 Percentage of viral vector in gene therapy clinical trials as of April 2019
Fig. 84 Global viral vector & plasmid DNA manufacturing market for gene therapy, 2017 - 2028 (USD Million)
Fig. 85 Global viral vector & plasmid DNA manufacturing market for cell therapy, 2017 - 2028 (USD Million)
Fig. 86 Strengths and weaknesses of viral vector vaccines
Fig. 87 Global viral vector & plasmid DNA manufacturing market for vaccinology, 2017 - 2028 (USD Million)
Fig. 88 Global viral vector & plasmid DNA manufacturing market for research applications, 2017 - 2028 (USD Million)
Fig. 89 Viral vector & plasmid DNA manufacturing market : End-use outlook and key takeaways
Fig. 90 Global viral vector & plasmid DNA manufacturing market: End-use movement analysis
Fig. 91 Global viral vector & plasmid DNA manufacturing market for pharmaceutical and biopharmaceutical companies, 2017 - 2028 (USD Million)
Fig. 92 Global viral vector & plasmid DNA manufacturing market for research institutes, 2017 - 2028
Fig. 93 Viral vector & plasmid DNA manufacturing market : Disease outlook and key takeaways
Fig. 94 Global viral vector & plasmid DNA manufacturing market: Disease movement analysis
Fig. 95 Global viral vector & plasmid DNA manufacturing market for cancer, 2017 - 2028 (USD Million)
Fig. 96 Global viral vector & plasmid DNA manufacturing market for genetic disorders, 2017 - 2028 (USD Million)
Fig. 97 Global viral vector & plasmid DNA manufacturing market for infectious diseases, 2017 - 2028 (USD Million)
Fig. 98 Global viral vector & plasmid DNA manufacturing market for other diseases, 2017 - 2028 (USD Million)
Fig. 99 Regional marketplace: Key takeaway
Fig. 100 Viral vector & plasmid DNA manufacturing market: Regional movement analysis
Fig. 101 North America viral vector & plasmid DNA manufacturing market, 2017 - 2028 (USD Million)
Fig. 102 U.S. viral vector & plasmid DNA manufacturing market, 2017 - 2028 (USD Million)
Fig. 103 Canada viral vector & plasmid DNA manufacturing market, 2017 - 2028 (USD Million)
Fig. 104 Europe viral vector & plasmid DNA manufacturing market, 2017 - 2028 (USD Million)
Fig. 105 U.K. viral vector & plasmid DNA manufacturing market, 2017 - 2028 (USD Million)
Fig. 106 Germany viral vector & plasmid DNA manufacturing market, 2017 - 2028 (USD Million)
Fig. 107 France viral vector & plasmid DNA manufacturing market, 2017 - 2028 (USD Million)
Fig. 108 Italy viral vector & plasmid DNA manufacturing market, 2017 - 2028 (USD Million)
Fig. 109 Spain viral vector & plasmid DNA manufacturing market, 2017 - 2028 (USD Million)
Fig. 110 Asia Pacific viral vector & plasmid DNA manufacturing market, 2017 - 2028 (USD Million)
Fig. 111 China viral vector & plasmid DNA manufacturing market, 2017 - 2028 (USD Million)
Fig. 112 Japan viral vector & plasmid DNA manufacturing market, 2017 - 2028 (USD Million)
Fig. 113 India viral vector & plasmid DNA manufacturing market, 2017 - 2028 (USD Million)
Fig. 114 South Korea viral vector & plasmid DNA manufacturing market, 2017 - 2028 (USD Million)
Fig. 115 Latin America viral vector & plasmid DNA manufacturing market, 2017 - 2028 (USD Million)
Fig. 116 Brazil viral vector & plasmid DNA manufacturing market, 2017 - 2028 (USD Million)
Fig. 117 Mexico viral vector & plasmid DNA manufacturing market, 2017 - 2028 (USD Million)
Fig. 118 MEA viral vector & plasmid DNA manufacturing market, 2017 - 2028 (USD Million)
Fig. 119 South Africa viral vector & plasmid DNA manufacturing market, 2017 - 2028 (USD Million)
Fig. 120 Saudi Arabia viral vector & plasmid DNA manufacturing market, 2017 - 2028 (USD Million)
Fig. 121 New developments-based initiatives by key market participants
Fig. 122 Impact analysis of new developments by key market participants
Fig. 123 Company/competition categorization
Fig. 124 Distribution by location of manufacturing facility
Fig. 125 CDMOs operating in China
Fig. 126 Distribution by scale of production
Fig. 127 Company mapping analysis, by manufacturing facility, type of organization, and purpose of production
Fig. 128 Key public companies: Heat map analysis
Fig. 129 List of companies with portfolio comprising antibody & viral vector-based therapeutic candidates
Fig. 130 Synergy analysis: Major deals & strategic alliances
Fig. 131 Participant categorization
Fig. 132 Strategy framework
Fig. 133 SWOT analysis: Merck
Fig. 134 SWOT analysis: Lonza
Fig. 135 SWOT analysis: FUJIFILM
Fig. 136 SWOT analysis: Cobra Biologics
Fig. 137 SWOT analysis: Brammer Bio
Fig. 138 SWOT analysis: Waisman Biomanufacturing
Fig. 139 SWOT analysis: Genezen
Fig. 140 SWOT analysis: YPOSKESI
Fig. 141 SWOT analysis: ABL Inc.
Fig. 142 SWOT analysis: Novasep Holding S.A.S
Fig. 143 SWOT analysis: Orgenesis Biotech Israel Ltd
Fig. 144 SWOT analysis: Vigene Biosciences
Fig. 145 SWOT analysis: GE Healthcare
Fig. 146 SWOT analysis: Cevec Pharmaceuticals GmbH
Fig. 147 SWOT analysis: Batavia Biosciences
Fig. 148 SWOT analysis: Biovion
Fig. 149 SWOT analysis: Wuxi AppTec Co Ltd.
Fig. 150 SWOT analysis: VGXI Inc.
Fig. 151 SWOT analysis: Paragon Servicest Inc.
Fig. 152 SWOT analysis: Lentigen Technology
Fig. 153 SWOT analysis: Sirion Biotech GmbH
Fig. 154 SWOT analysis: Virovek Incorporation
Fig. 155 SWOT analysis: BioNTech
Fig. 156 SWOT analysis: VIVEbiotech
Fig. 157 SWOT analysis: Creative Biogene
Fig. 158 SWOT analysis: Vibalogics GmbH
Fig. 159 SWOT analysis: Takara BioInc.
Fig. 160 SWOT analysis: Cell and Gene Therapy Catapult
Fig. 161 SWOT analysis: Bluebird Bio Inc.
Fig. 162 SWOT analysis: Addgene Inc.
Fig. 163 SWOT analysis: Aldevron LLC
Fig. 164 SWOT analysis: Audentis
Fig. 165 SWOT analysis: BioMarin Pharmaceuticals
Fig. 166 SWOT analysis: REGENXBIO Inc.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[世界のウイルスベクター&プラスミドDNA製造市場2021-2028:ベクタータイプ別(AAV、レンチウイルス)、ワークフロー別、用途別、最終用途別、疾患別、地域別]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆